Mechanisms of action of antiestrogens: Relevance to clinical benefits and risks

被引：23

作者：

Carmichael, PL ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Sch Med, Div Biomed Sci, London SW7 2AZ, England

来源：

CANCER INVESTIGATION | 1998年 / 16卷 / 08期

关键词：

D O I：

10.3109/07357909809032891

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：604 / 611

页数：8

共 53 条

[1]

ABE O, 1992, LANCET, V339, P71

[2]

Barakat R R, 1995, Oncology (Williston Park), V9, P129

[3] ROLE OF THE 2 ACTIVATING DOMAINS OF THE ESTROGEN-RECEPTOR IN THE CELL-TYPE AND PROMOTER-CONTEXT DEPENDENT AGONISTIC ACTIVITY OF THE ANTIESTROGEN 4-HYDROXYTAMOXIFEN [J].

BERRY, M ;

METZGER, D ;

CHAMBON, P .

EMBO JOURNAL, 1990, 9 (09) :2811-2818

[4]

BUTTA A, 1992, CANCER RES, V52, P4261

[5] PHASE-I TRIAL OF DROLOXIFENE IN PATIENTS WITH METASTATIC BREAST-CANCER [J].

BUZDAR, AU ;

KAU, S ;

HORTOBAGYI, GN ;

THERIAULT, RL ;

BOOSER, D ;

HOLMES, FA ;

WALTERS, R ;

KRAKOFF, IH .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1994, 33 (04) :313-316

[6]

CARMICHAEL PL, 1996, CANCER RES, V56, P1474

[7] HUMAN UTERINE TISSUE THROUGHOUT THE MENSTRUAL-CYCLE EXPRESSES TRANSFORMING GROWTH-FACTOR-BETA-1 (TGF-BETA-1), TGF-BETA-2, TGF-BETA-3, AND TGF-BETA TYPE-II RECEPTOR MESSENGER-RIBONUCLEIC-ACID AND PROTEIN AND CONTAINS [I-125] TGF-BETA-1-BINDING SITES [J].

CHEGINI, N ;

ZHAO, Y ;

WILLIAMS, RS ;

FLANDERS, KC .

ENDOCRINOLOGY, 1994, 135 (01) :439-449

[8]

COHEN C, 1977, SEMIN ONCOL S1, V24, pS55

[9]

COOMBES RC, 1995, CANCER RES, V55, P1070

[10]

COX DA, 1995, CELL BIOL INT, V19, P357, DOI 10.1006/cbir.1995.1082

← 1 2 3 4 5 6 →